Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of Circulating Tumor DNA to Confirm Somatic KRAS Mutations

30 Jul 2009

Abstract excerpt

KRAS mutations have clearly emerged as a pharmacogenomic marker that can predict which metastatic colorectal cancers will be resistant to treatment with antibodies that inhibit the epidermal growth factor receptor (EGFR) ( 1 , 2 ). The evaluation of patients for mutations in KRAS is rapidly becoming part of routine practice in clinical oncology and so far has relied mostly on formalin-fixed paraffin-embedded...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Colorectal Cancer Treatments and Studies
Share to Genetic factors in colorectal cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19641175
DOI: 10.1093/jnci/djp240

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of Circulating Tumor DNA to Confirm Somatic KRAS MutationsPMID 19641175Read ↗

Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing.Semantic proximity Read ↗

Analysis of KRAS mutations in circulating tumor DNA and colorectal cancer tissue.Semantic proximity Read ↗

Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial.Semantic proximity Read ↗

Utility of KRAS mutation detection using circulating cell-free DNA from patients with colorectal cancer.Semantic proximity Read ↗

Comparison of KRAS Mutation Assessment in Tumor DNA and Circulating Free DNA in Plasma and Serum SamplesSemantic proximity Read ↗

Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancer.Semantic proximity Read ↗

Laboratory methods for<i>KRAS</i>mutation analysisSemantic proximity Read ↗

Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls.Semantic proximity Read ↗

KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.Semantic proximity Read ↗

RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.Semantic proximity Read ↗

Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization.Semantic proximity Read ↗

Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.